Bloch Stephen M sold $6.4M of LQDA (indirect holdings)

Bloch Stephen M sold 235,477 indirectly-held shares of Liquidia Corp (LQDA) at $27.13 ($6.39M total) on 2026-10-05.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Oct 7, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
high confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The director's full divestiture may be interpreted as a negative signal, potentially prompting short sellers and reducing buyer interest.

02

Market read

Primary insider sale of a director-sized stake; modest materiality but new information for traders.

03

What to watch

No prior insider purchases; the director may be diversifying holdings unrelated to company outlook.

Relevance 6/10Novelty 6/10Timing: post‑market filing

Background

SEC Form 4 filing discloses insider transactions. This is the first public report of the director's complete exit from Liquidia.

Company-level read

Ticker impact

$LQDABearishHigh confidence
Context

Director Stephen Bloch sold 235,477 shares at $27.13 each, total $6.4M, leaving zero holdings.

Expected impact

downward pressure as the market prices in the insider sell.

Evidence & confidence

A director exiting with a $6.4M stake is material and suggests reduced confidence, prompting short-term sell pressure.

Market effects

Biotech sector may see slight sell pressure from perceived insider weakness.

U.S. equity market, particularly Nasdaq biotech listings.

Limited to investors tracking Liquidia and related biotech peers.

Counterpoint

The sale could be driven by personal liquidity needs, not a lack of confidence in the company.

Key entities

  • Liquidia Corp

    Biotech firm listed on Nasdaq (LQDA).

  • Stephen M. Bloch

    Director of Liquidia who sold his entire stake.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.